loadpatents
name:-0.0061988830566406
name:-0.020945072174072
name:-0.0064589977264404
Friedmann; Theodore Patent Filings

Friedmann; Theodore

Patent Applications and Registrations

Patent applications and USPTO patent grants for Friedmann; Theodore.The latest application filed is for "products and methods for controlling the suppression of the neoplastic phenotype".

Company Profile
0.12.0
  • Friedmann; Theodore - La Jolla CA
  • Friedmann; Theodore - San Diego CA
*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.
Patent Activity
PatentDate
Products and methods for controlling the suppression of the neoplastic phenotype
Grant 7,060,688 - Lee , et al. June 13, 2
2006-06-13
Method for retrovirus vector production by separated gag and pol expression
Grant 6,451,304 - Friedmann , et al. September 17, 2
2002-09-17
Inducible expression system
Grant 6,432,705 - Yee , et al. August 13, 2
2002-08-13
Transfection in serum-containing media
Grant 6,171,862 - Abe , et al. January 9, 2
2001-01-09
VSV G pseusdotyped retroviral vectors
Grant 5,817,491 - Yee , et al. October 6, 1
1998-10-06
Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system
Grant 5,762,926 - Gage , et al. June 9, 1
1998-06-09
Packaging cell lines for pseudotyped retroviral vectors
Grant 5,739,018 - Miyanohara , et al. April 14, 1
1998-04-14
Cancer immunotherapy with carrier cells
Grant 5,674,486 - Sobol , et al. October 7, 1
1997-10-07
Use of VSV-G pseudotyped vectors for transfer of genes into embryos
Grant 5,670,354 - Burns , et al. September 23, 1
1997-09-23
Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system
Grant 5,650,148 - Gage , et al. July 22, 1
1997-07-22
Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors
Grant 5,512,421 - Burns , et al. April 30, 1
1996-04-30
Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
Grant 5,082,670 - Gage , et al. January 21, 1
1992-01-21
Company Registrations

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed